LNCR3
MCID: LNG064
MIFTS: 78

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 56 13 71
Lung Adenocarcinoma 12 52 29 6 15 17
Adenocarcinoma of Lung 56 12 74 43 71
Adenocarcinoma of Lung, Susceptibility to 56
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 71
Nonsmall Cell Adenocarcinoma 12
Lung Adenocarcinomas 15
Adenocarcinoma Lung 54
Lncr3 56

Classifications:



External Ids:

Disease Ontology 12 DOID:3910
OMIM 56 612571
MeSH 43 D000077192
NCIt 49 C27745 C3512
SNOMED-CT 67 254626006
UMLS 71 C0152013 C1335060 C2675497

Summaries for Lung Cancer Susceptibility 3

NIH Rare Diseases : 52 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection . Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy , chemotherapy , targeted therapy , and/or watchful waiting .

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to lung cancer and mucinous lung adenocarcinoma. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Endostar protein and Endostatins have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A lung cancer that derives from epithelial cells of glandular origin.

Wikipedia : 74 Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer,... more...

More information from OMIM: 612571

Related Diseases for Lung Cancer Susceptibility 3

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 883)
# Related Disease Score Top Affiliating Genes
1 lung cancer 36.7 TP53 STK11 SMAD4 ROS1 RAF1 PRKN
2 mucinous lung adenocarcinoma 35.8 ROS1 KRAS HRAS EGFR
3 lung squamous cell carcinoma 35.6 TP53 STK11 SMAD4 ROS1 PIK3CA NFE2L2
4 signet ring lung adenocarcinoma 35.4 EGFR ALK
5 adenocarcinoma 34.5 TP53 STK11 SMAD4 ROS1 RAF1 PIK3CA
6 hepatocellular carcinoma 33.4 TP53 STK11 SMAD4 RAF1 PIK3CA NRAS
7 pancreatic adenocarcinoma 33.3 TP53 SMAD4 RAF1 PIK3CA MAP2K1 KRAS
8 colorectal cancer 33.3 TP53 STK11 SMAD4 ROS1 RAF1 PIK3CA
9 breast cancer 33.3 TP53 STK11 SMAD4 RAF1 PIK3CA NRAS
10 sarcoma 33.2 TP53 ROS1 RAF1 PIK3CA NRAS MAP2K1
11 glioblastoma multiforme 33.2 TP53 ROS1 RAF1 PIK3CA NRAS MAP2K1
12 neuroblastoma 33.2 TP53 PRKN PIK3CA NRAS NFE2L2 MAP2K1
13 pancreatic cancer 33.1 TP53 STK11 SMAD4 RAF1 PIK3CA MAP2K1
14 prostate cancer 33.1 TP53 SMAD4 RAF1 PIK3CA NFE2L2 MAP2K1
15 gastric cancer 33.0 TP53 SMAD4 RAF1 PIK3CA NRAS NFE2L2
16 melanoma 33.0 TP53 STK11 RAF1 PIK3CA NRAS MAP2K1
17 bladder cancer 33.0 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
18 esophageal cancer 32.9 TP53 STK11 SMAD4 PIK3CA KRAS HRAS
19 colon adenocarcinoma 32.9 TP53 SMAD4 PIK3CA NRAS KRAS ERBB2
20 squamous cell carcinoma 32.8 TP53 STK11 SMAD4 PIK3CA NFE2L2 MAP2K1
21 ovarian cancer 32.8 TP53 STK11 SMAD4 RAF1 PRKN PIK3CA
22 adenoma 32.8 TP53 SMAD4 PIK3CA KRAS CTNNB1 BRAF
23 large cell carcinoma 32.8 STK11 ROS1 KRAS HRAS ERBB2 EGFR
24 cholangiocarcinoma 32.7 TP53 SMAD4 ROS1 RAF1 PIK3CA KRAS
25 acute promyelocytic leukemia 32.7 TP53 SMAD4 PIK3CA NRAS NFE2L2 MAP2K1
26 cervical cancer 32.7 TP53 STK11 SMAD4 PIK3CA NFE2L2 HRAS
27 endometrial cancer 32.7 TP53 SMAD4 PIK3CA NRAS KRAS HRAS
28 li-fraumeni syndrome 32.7 TP53 STK11 SMAD4 KRAS HRAS ERBB2
29 gastric adenocarcinoma 32.6 TP53 SMAD4 ROS1 RAF1 PIK3CA NRAS
30 lynch syndrome 32.6 TP53 STK11 SMAD4 PIK3CA KRAS HRAS
31 small cell carcinoma 32.5 TP53 KRAS EGFR ALK
32 nasopharyngeal carcinoma 32.5 TP53 SMAD4 RAF1 PIK3CA NRAS HRAS
33 bladder urothelial carcinoma 32.5 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
34 leukemia, chronic lymphocytic 32.5 TP53 PIK3CA NRAS KRAS HRAS ERBB2
35 renal cell carcinoma, nonpapillary 32.5 TP53 RAF1 PIK3CA NRAS HRAS EGFR
36 brain cancer 32.4 TP53 PIK3CA NRAS HRAS EGFR CTNNB1
37 colorectal adenocarcinoma 32.4 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
38 melanoma, uveal 32.3 TP53 SMAD4 RAF1 PIK3CA NRAS MAP2K1
39 renal cell carcinoma, papillary, 1 32.3 TP53 PIK3CA NRAS NFE2L2 HRAS FGFR3
40 leukemia, acute myeloid 32.3 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
41 neurofibromatosis, type ii 32.2 TP53 HRAS ERBB2 EGFR CTNNB1
42 thyroid carcinoma 32.2 PIK3CA HRAS BRAF
43 suppression of tumorigenicity 12 32.2 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
44 ovarian serous cystadenocarcinoma 32.2 TP53 SMAD4 PIK3CA NRAS KRAS HRAS
45 lung adenoma 32.2 TP53 RAF1 KRAS HRAS EGFR
46 ovary adenocarcinoma 32.2 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
47 intrahepatic cholangiocarcinoma 32.2 TP53 SMAD4 KRAS ERBB2 EGFR CTNNB1
48 adenoid cystic carcinoma 32.2 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
49 glioma 32.1 TP53 PIK3CA ERBB2 EGFR CDK4 BRAF
50 in situ carcinoma 32.1 TP53 PIK3CA HRAS ERBB2 EGFR CTNNB1

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.09 BRAF EGFR PIK3CA HRAS KRAS
2 Decreased viability GR00055-A-2 11.09 BRAF EGFR PIK3CA HRAS KRAS
3 Decreased viability GR00055-A-3 11.09 KRAS
4 Decreased viability GR00106-A-0 11.09 KRAS
5 Decreased viability GR00107-A-1 11.09 MAP2K1
6 Decreased viability GR00221-A-1 11.09 ALK EGFR PIK3CA FGFR3 HRAS NRAS
7 Decreased viability GR00221-A-2 11.09 PIK3CA FGFR3 HRAS KRAS RAF1 ROS1
8 Decreased viability GR00221-A-3 11.09 ERBB2 FGFR3 HRAS MAP2K1 NRAS
9 Decreased viability GR00221-A-4 11.09 ALK BRAF EGFR ERBB2 PIK3CA
10 Decreased viability GR00249-S 11.09 ALK BRAF FGFR3 ROS1
11 Decreased viability GR00301-A 11.09 BRAF KRAS RAF1
12 Decreased viability GR00342-S-1 11.09 ROS1
13 Decreased viability GR00381-A-1 11.09 BRAF KRAS
14 Decreased viability GR00402-S-2 11.09 PIK3CA RAF1
15 Decreased substrate adherent cell growth GR00193-A-1 10.25 STK11 RAF1 ROS1
16 Decreased substrate adherent cell growth GR00193-A-2 10.25 CDK4 ALK EGFR RAF1 ROS1
17 Decreased substrate adherent cell growth GR00193-A-3 10.25 BRAF CDK4 FGFR3 STK11
18 Decreased substrate adherent cell growth GR00193-A-4 10.25 BRAF CDK4
19 Decreased cell migration GR00055-A-1 10.2 ALK CDK4 FGFR3
20 Decreased cell migration GR00055-A-3 10.2 BRAF EGFR HRAS PIK3CA
21 Decreased cell–culture–derived Hepatitis C virus (HCVcc; Luc–Jc1) infection GR00234-A-2 9.73 BRAF CDK4 EGFR STK11
22 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.71 BRAF CDK4 EGFR STK11
23 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.67 ALK BRAF FGFR3 RAF1
24 Reduced mammosphere formation GR00396-S 9.56 BRAF CDK4 EGFR HRAS KRAS NFE2L2
25 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 APC BRAF CDK4 ROS1 SMAD4
26 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.85 CTNNB1

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 APC BRAF CDK4 CTNNB1 EGFR ERBB2
2 growth/size/body region MP:0005378 10.57 ALK APC BRAF CDK4 CTNNB1 EGFR
3 behavior/neurological MP:0005386 10.56 ALK APC BRAF CDK4 CTNNB1 ERBB2
4 cardiovascular system MP:0005385 10.56 APC BRAF CDK4 CTNNB1 EGFR ERBB2
5 homeostasis/metabolism MP:0005376 10.54 ALK APC BRAF CDK4 CTNNB1 EGFR
6 integument MP:0010771 10.53 ALK APC BRAF CDK4 CTNNB1 EGFR
7 craniofacial MP:0005382 10.52 APC BRAF CDK4 CTNNB1 EGFR ERBB2
8 endocrine/exocrine gland MP:0005379 10.5 ALK APC BRAF CDK4 CTNNB1 EGFR
9 digestive/alimentary MP:0005381 10.49 APC BRAF CDK4 CTNNB1 EGFR ERBB2
10 mortality/aging MP:0010768 10.49 ALK APC BRAF CDK4 CTNNB1 EGFR
11 embryo MP:0005380 10.48 APC BRAF CDK4 CTNNB1 EGFR ERBB2
12 neoplasm MP:0002006 10.43 ALK APC BRAF CDK4 CTNNB1 EGFR
13 nervous system MP:0003631 10.41 ALK APC BRAF CDK4 CTNNB1 EGFR
14 immune system MP:0005387 10.4 APC BRAF CDK4 CTNNB1 EGFR FGFR3
15 hematopoietic system MP:0005397 10.39 APC BRAF CDK4 CTNNB1 EGFR FGFR3
16 normal MP:0002873 10.33 APC BRAF CDK4 CTNNB1 EGFR ERBB2
17 muscle MP:0005369 10.31 APC BRAF CDK4 CTNNB1 EGFR ERBB2
18 liver/biliary system MP:0005370 10.3 APC BRAF CDK4 CTNNB1 EGFR KRAS
19 hearing/vestibular/ear MP:0005377 10.24 APC BRAF CTNNB1 EGFR FGFR3 KRAS
20 limbs/digits/tail MP:0005371 10.24 APC BRAF CTNNB1 EGFR ERBB2 FGFR3
21 no phenotypic analysis MP:0003012 10.21 CTNNB1 EGFR FGFR3 HRAS KRAS NRAS
22 reproductive system MP:0005389 10.13 ALK APC BRAF CDK4 CTNNB1 EGFR
23 renal/urinary system MP:0005367 10.1 APC BRAF CDK4 CTNNB1 EGFR FGFR3
24 pigmentation MP:0001186 10.02 ALK APC BRAF CDK4 CTNNB1 EGFR
25 respiratory system MP:0005388 9.97 ALK BRAF CTNNB1 EGFR ERBB2 FGFR3
26 skeleton MP:0005390 9.91 ALK APC BRAF CDK4 CTNNB1 EGFR
27 vision/eye MP:0005391 9.47 ALK APC BRAF CDK4 CTNNB1 EGFR

Drugs & Therapeutics for Lung Cancer Susceptibility 3

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Endostar protein Phase 4
2 Endostatins Phase 4 71581480
3
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
4
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
5
Ipilimumab Approved Phase 3 477202-00-9
6
Ceritinib Approved Phase 3 1032900-25-6
7
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
8
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
9
Pembrolizumab Approved Phase 3 1374853-91-4
10
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
11
leucovorin Approved Phase 3 58-05-9 6006 143
12
Bevacizumab Approved, Investigational Phase 3 216974-75-3
13
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
14
Gemcitabine Approved Phase 3 95058-81-4 60750
15
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
16
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
17
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
20
Cobalamin Experimental Phase 3 13408-78-1 6857388
21 Shark Cartilage Phase 3
22 2,2'-dithiodiethanesulfonic acid Phase 3
23 Immunoglobulins, Intravenous Phase 3
24 Endothelial Growth Factors Phase 3
25 Immunoglobulin G Phase 3
26 Immunologic Factors Phase 2, Phase 3
27 Pharmaceutical Solutions Phase 2, Phase 3
28 Vaccines Phase 2, Phase 3
29 Anesthetics Phase 3
30 Liver Extracts Phase 3
31 Vitamin B Complex Phase 3
32 Folic Acid Antagonists Phase 3
33 Immunosuppressive Agents Phase 3
34 Folate Phase 3
35 Vitamin B9 Phase 3
36 Antirheumatic Agents Phase 3
37 Angiogenesis Inhibitors Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Analgesics, Non-Narcotic Phase 3
40 Analgesics Phase 3
41 Cyclooxygenase Inhibitors Phase 3
42 Anti-Inflammatory Agents Phase 3
43 Anti-Inflammatory Agents, Non-Steroidal Phase 3
44 Anti-Infective Agents Phase 3
45 Antiviral Agents Phase 3
46 Antimetabolites Phase 3
47 Vitamins Phase 3
48 Vitamin B 12 Phase 3
49 Vitamin B12 Phase 3
50 Cyclooxygenase 2 Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 331)
# Name Status NCT ID Phase Drugs
1 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
2 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
3 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
7 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
8 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
9 Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors(TKIs)in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study Not yet recruiting NCT04401059 Phase 4 Elemene plus First-generation EGFR-TKIs;First-generation EGFR-TKIs
10 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Unknown status NCT02518802 Phase 3 Gefitinib;Pemetrexed
11 A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy Unknown status NCT01066195 Phase 3 iressa;alimta
12 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
13 Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation Completed NCT01719536 Phase 3 Icotinib;Chemotherapy
14 A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung Completed NCT00455936 Phase 3 Gefitinib
15 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
16 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
17 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
18 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
19 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
20 Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
21 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
22 Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
23 Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial Completed NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
24 Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
25 Tyrosine-kinase Inhibitor (TKI) With or Without SBRT in Newly Diagnosed Advanced Staged Lung Adenocarcinoma Recruiting NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
26 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Recruiting NCT02281708 Phase 3 vinorelbine plus cisplatin
27 Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS Recruiting NCT03391869 Phase 3
28 A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Recruiting NCT03676192 Phase 3 CT-16;Avastin
29 Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study Recruiting NCT02125240 Phase 3 Icotinib;Placebo
30 A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting NCT04248829 Phase 3 Lazertinib 240 mg/160 mg;Gefitinib 250 mg;Lazertinib-matching placebo 240 mg/160 mg;Gefitinib-matching placebo 250 mg
31 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
32 Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations Who Did Not Progress After Pemetrexed in Combination With Platinum-based Chemotherapy:a Single-arm, Open, Multicenter Clinical Study. Recruiting NCT03992885 Phase 3 Icotinib
33 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
34 A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
35 A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
36 Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
37 Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer Enrolling by invitation NCT01782287 Phase 2, Phase 3
38 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
39 Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study Not yet recruiting NCT04339218 Phase 3 Pembrolizumab;Pemetrexed;Carboplatin
40 A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma Terminated NCT01798485 Phase 3 Docetaxel;Ganetespib
41 Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases Terminated NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
42 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
43 A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Unknown status NCT03376737 Phase 2 Apatinib
44 The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar Unknown status NCT01564329 Phase 2 endostar
45 Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial Unknown status NCT02951637 Phase 2 Pemetrexed plus carboplatin combined with gefitinib;Gefitinib
46 Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study Unknown status NCT02621333 Phase 2 chemotherapy
47 High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Unknown status NCT02284490 Phase 2 pemetrexed
48 A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy Unknown status NCT02787447 Phase 2 TKI;Thymosin Alpha 1
49 Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study. Unknown status NCT02704767 Phase 2 Apatinib;Tarceva;Placebo
50 Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR) Unknown status NCT02946359 Phase 2 Crizotinib, bevacizumab

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Genetic Tests for Lung Cancer Susceptibility 3

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 29

Anatomical Context for Lung Cancer Susceptibility 3

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

40
Lung, Brain, Breast, Lymph Node, Thyroid, Testes, Bone

Publications for Lung Cancer Susceptibility 3

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 14831)
# Title Authors PMID Year
1
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. 56
21725308 2011
2
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. 56
19836008 2009
3
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 56
19151717 2009
4
Lung cancer susceptibility locus at 5p15.33. 56
18978790 2008
5
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 56
18978787 2008
6
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. 54 61
19854534 2010
7
Comparative proteome analysis of human adenocarcinoma. 61 54
19381893 2010
8
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 61 54
20347035 2010
9
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. 61 54
20150826 2010
10
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. 54 61
19589612 2010
11
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. 54 61
20061363 2010
12
Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. 61 54
20222723 2010
13
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 61 54
20154720 2010
14
Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. 54 61
20146241 2010
15
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. 54 61
19540014 2010
16
Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation. 54 61
19949890 2010
17
Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. 61 54
20350214 2010
18
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. 61 54
19556604 2010
19
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. 61 54
19130320 2010
20
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. 61 54
20093391 2010
21
EGFR mutations and the terminal respiratory unit. 54 61
20135199 2010
22
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. 61 54
20052735 2010
23
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. 54 61
20007486 2010
24
Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. 61 54
19875972 2010
25
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. 54 61
20007840 2010
26
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. 61 54
19947923 2010
27
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. 61 54
20036260 2010
28
Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. 54 61
19887599 2009
29
COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. 61 54
19815609 2009
30
A region within the 5'-untranslated region of hypoxia-inducible factor-1alpha mRNA mediates its turnover in lung adenocarcinoma cells. 54 61
19887373 2009
31
An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. 54 61
19899793 2009
32
ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. 54 61
20003391 2009
33
Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. 61 54
20003463 2009
34
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. 61 54
19826035 2009
35
Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells. 61 54
19107575 2009
36
Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. 61 54
19760750 2009
37
Roles of pathologists in molecular targeted cancer therapy. 61 54
19891708 2009
38
Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. 61 54
19724887 2009
39
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. 54 61
19685508 2009
40
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. 61 54
19826477 2009
41
The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. 54 61
19639960 2009
42
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. 54 61
19724844 2009
43
Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells. 54 61
19571039 2009
44
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 54 61
19794967 2009
45
Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. 54 61
19854132 2009
46
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. 54 61
19706809 2009
47
Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. 54 61
19704257 2009
48
Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1. 61 54
19570984 2009
49
Restoration of SOCS3 suppresses human lung adenocarcinoma cell growth by downregulating activation of Erk1/2, Akt apart from STAT3. 61 54
19524687 2009
50
Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. 61 54
19561538 2009

Variations for Lung Cancer Susceptibility 3

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 398) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_001126112.2(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_001126112.2(TP53):c.730G>A (p.Gly244Ser)SNV Pathogenic 376600 rs1057519989 17:7577551-7577551 17:7674233-7674233
3 TP53 NM_001126112.2(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
4 TP53 NM_001126112.2(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
5 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
6 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
7 TP53 NM_001126112.2(TP53):c.644G>T (p.Ser215Ile)SNV Pathogenic 376660 rs587782177 17:7578205-7578205 17:7674887-7674887
8 TP53 NM_001126112.2(TP53):c.722C>A (p.Ser241Tyr)SNV Pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
9 TP53 NM_001126112.2(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
10 ERBB2 NM_004448.3(ERBB2):c.2606T>G (p.Leu869Arg)SNV Pathogenic 431024 rs1131692237 17:37881414-37881414 17:39725161-39725161
11 EGFR NM_005228.5(EGFR):c.988G>A (p.Glu330Lys)SNV Pathogenic 560008 rs139429793 7:55223621-55223621 7:55155928-55155928
12 PRKN NM_013988.2(PARK2):c.(8_8)_(171_171)+180544deldeletion Pathogenic 7049 6:162262766-162727661
13 SMAD4 NM_005359.6(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
14 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
15 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
16 TP53 NM_001126112.2(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
17 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
18 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
19 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
20 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
21 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
22 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
23 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
24 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
25 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
26 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
27 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
28 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
29 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
30 RAF1 NM_001354689.3(RAF1):c.770C>T (p.Ser257Leu)SNV Pathogenic 13957 rs80338796 3:12645699-12645699 3:12604200-12604200
31 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu)SNV Pathogenic,drug response 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
32 BRAF NM_001374258.1(BRAF):c.1921A>G (p.Lys641Glu)SNV Pathogenic 13966 rs121913364 7:140453134-140453134 7:140753334-140753334
33 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
34 BRAF NM_001374258.1(BRAF):c.1526G>C (p.Gly509Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
35 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
36 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
37 ERBB2 NM_004448.3(ERBB2):c.2328_2336dup (p.Val777_Ser779dup)duplication Pathogenic 13876 rs587776805 17:37880998-37880999 17:39724745-39724746
38 FGFR3 NM_001163213.1(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
39 CDK4 NM_000075.4(CDK4):c.70C>T (p.Arg24Cys)SNV Pathogenic 16928 rs11547328 12:58145431-58145431 12:57751648-57751648
40 CDK4 NM_000075.4(CDK4):c.71G>A (p.Arg24His)SNV Pathogenic 16929 rs104894340 12:58145430-58145430 12:57751647-57751647
41 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
42 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val)SNV Pathogenic 40387 rs397507483 7:140453148-140453148 7:140753348-140753348
43 SMAD4 NM_005359.6(SMAD4):c.1082G>A (p.Arg361His)SNV Pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
44 BRAF NM_001374258.1(BRAF):c.1526G>T (p.Gly509Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
45 EGFR NM_005228.5(EGFR):c.2156G>C (p.Gly719Ala)SNV Pathogenic 45225 rs121913428 7:55241708-55241708 7:55174015-55174015
46 TP53 NM_001126112.2(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
47 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
48 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
49 TP53 NM_001126112.2(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
50 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification APOA1BP Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification PVRL4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma

Expression for Lung Cancer Susceptibility 3

LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C type 1 (slow) Lung - 5.28 0.000
2 COL11A1 collagen, type XI, alpha 1 Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end product-specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4, adipocyte Lung - 4.32 0.000
8 CDH3 cadherin 3, type 1, P-cadherin (placental) Lung + 4.31 0.000
9 FOSB FBJ murine osteosarcoma viral oncogene homolog B Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3, member B Lung - 4.18 0.000
12 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor, Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen, type X, alpha 1 Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor (G protein-coupled) activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family, member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 (amisyn) Lung - 3.59 0.000
22 TMPRSS4 transmembrane protease, serine 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibrillar-associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Lung + 3.47 0.000
26 TOP2A topoisomerase (DNA) II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase IV Lung - 3.38 0.000
29 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 (Psf2 homolog) Lung + 3.29 0.000
32 NEK2 NIMA-related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor-like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Lung - 3.17 0.000
38 FIGF c-fos induced growth factor (vascular endothelial growth factor D) Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen, type I, alpha 1 Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for Lung Cancer Susceptibility 3

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.39 TP53 STK11 SMAD4 RAF1 PIK3CA NRAS
2
Show member pathways
14.22 TP53 RAF1 PRKN PIK3CA NRAS MAP2K1
3
Show member pathways
14.02 TP53 STK11 SMAD4 ROS1 RAF1 NRAS
4
Show member pathways
13.95 SMAD4 RAF1 PIK3CA NRAS MAP2K1 KRAS
5
Show member pathways
13.94 TP53 SMAD4 ROS1 RAF1 NRAS MAP2K1
6
Show member pathways
13.92 TP53 SMAD4 ROS1 RAF1 NRAS MAP2K1
7
Show member pathways
13.81 SMAD4 ROS1 RAF1 NRAS MAP2K1 KRAS
8
Show member pathways
13.78 TP53 SMAD4 ROS1 RAF1 PIK3CA NRAS
9
Show member pathways
13.75 SMAD4 RAF1 PIK3CA NRAS MAP2K1 KRAS
10
Show member pathways
13.68 TP53 RAF1 PRKN PIK3CA NRAS KRAS
11
Show member pathways
13.65 TP53 ROS1 RAF1 NRAS KRAS HRAS
12
Show member pathways
13.61 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
13
Show member pathways
13.61 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
14
Show member pathways
13.57 ROS1 RAF1 NRAS MAP2K1 KRAS HRAS
15
Show member pathways
13.52 ROS1 RAF1 NRAS MAP2K1 KRAS HRAS
16
Show member pathways
13.49 SMAD4 NRAS KRAS HRAS FGFR3 ERBB2
17
Show member pathways
13.45 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
18
Show member pathways
13.43 TP53 RAF1 PRKN PIK3CA NRAS NFE2L2
19
Show member pathways
13.33 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
20
Show member pathways
13.33 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
21
Show member pathways
13.32 STK11 RAF1 NRAS MAP2K1 KRAS HRAS
22
Show member pathways
13.31 TP53 SMAD4 RAF1 PIK3CA NRAS MAP2K1
23
Show member pathways
13.28 RAF1 NRAS MAP2K1 KRAS HRAS EGFR
24
Show member pathways
13.25 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
25
Show member pathways
13.22 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
26
Show member pathways
13.19 RAF1 NRAS MAP2K1 KRAS HRAS CTNNB1
27
Show member pathways
13.18 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
28
Show member pathways
13.18 RAF1 NRAS MAP2K1 KRAS HRAS EGFR
29
Show member pathways
13.18 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
30
Show member pathways
13.15 STK11 RAF1 PIK3CA NRAS MAP2K1 KRAS
31
Show member pathways
13.14 ROS1 RAF1 FGFR3 ERBB2 EGFR ALK
32
Show member pathways
13.14 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
33
Show member pathways
13.12 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
34
Show member pathways
13.11 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
35
Show member pathways
13.09 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
36
Show member pathways
13.05 RAF1 NRAS MAP2K1 KRAS HRAS CTNNB1
37 13.05 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
38
Show member pathways
13.02 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
39
Show member pathways
13.01 TP53 PIK3CA NRAS KRAS HRAS FGFR3
40
Show member pathways
13 TP53 STK11 RAF1 PIK3CA NRAS MAP2K1
41
Show member pathways
12.99 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
42
Show member pathways
12.98 RAF1 PIK3CA MAP2K1 KRAS HRAS BRAF
43
Show member pathways
12.97 TP53 RAF1 PIK3CA NRAS MAP2K1 KRAS
44
Show member pathways
12.95 TP53 RAF1 PIK3CA MAP2K1 CDK4
45
Show member pathways
12.95 TP53 RAF1 NRAS MAP2K1 KRAS HRAS
46
Show member pathways
12.94 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
47
Show member pathways
12.94 RAF1 NRAS MAP2K1 KRAS HRAS EGFR
48
Show member pathways
12.94 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS
49
Show member pathways
12.91 PIK3CA NRAS MAP2K1 KRAS HRAS
50 12.91 RAF1 PIK3CA NRAS MAP2K1 KRAS HRAS

GO Terms for Lung Cancer Susceptibility 3

Cellular components related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.31 TP53 STK11 SMAD4 RAF1 PRKN NFE2L2
2 membrane GO:0016020 10.3 TP53 STK11 ROS1 RAF1 PIK3CA NRAS
3 plasma membrane GO:0005886 10.13 ROS1 RAF1 PIK3CA NRAS NFE2L2 MAP2K1
4 cytosol GO:0005829 10.03 TP53 STK11 SMAD4 RAF1 PRKN PIK3CA
5 Golgi apparatus GO:0005794 10.01 RAF1 PRKN NRAS NFE2L2 MAP2K1 HRAS
6 protein-containing complex GO:0032991 9.95 TP53 PRKN EGFR CTNNB1 CDK4 ALK
7 centrosome GO:0005813 9.91 TP53 SMAD4 NFE2L2 CTNNB1 APC
8 cytoplasm GO:0005737 9.89 TP53 STK11 SMAD4 RAF1 PRKN PIK3CA
9 focal adhesion GO:0005925 9.85 MAP2K1 KRAS FGFR3 EGFR CTNNB1
10 transcription factor complex GO:0005667 9.8 TP53 SMAD4 CTNNB1 CDK4
11 receptor complex GO:0043235 9.72 ROS1 FGFR3 ERBB2 EGFR ALK
12 perinuclear region of cytoplasm GO:0048471 9.23 ROS1 PRKN HRAS ERBB2 EGFR CTNNB1

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 RAF1 NRAS MAP2K1 KRAS HRAS ERBB2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 TP53 SMAD4 RAF1 PRKN NFE2L2 HRAS
3 cell differentiation GO:0030154 10.22 STK11 SMAD4 ROS1 RAF1 EGFR CTNNB1
4 positive regulation of transcription, DNA-templated GO:0045893 10.16 TP53 SMAD4 NFE2L2 MAP2K1 EGFR CTNNB1
5 intracellular signal transduction GO:0035556 10.11 SMAD4 RAF1 ERBB2 EGFR BRAF
6 positive regulation of cell proliferation GO:0008284 10.09 KRAS HRAS FGFR3 ERBB2 EGFR CTNNB1
7 regulation of apoptotic process GO:0042981 10.04 TP53 RAF1 PRKN CTNNB1 ALK
8 heart development GO:0007507 10.03 TP53 RAF1 MAP2K1 ERBB2 CTNNB1
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 MAP2K1 HRAS FGFR3 EGFR BRAF
10 negative regulation of cell proliferation GO:0008285 10.01 TP53 STK11 SMAD4 RAF1 MAP2K1 HRAS
11 negative regulation of gene expression GO:0010629 10 TP53 ROS1 PRKN MAP2K1 HRAS CTNNB1
12 T cell receptor signaling pathway GO:0050852 9.99 STK11 PIK3CA HRAS BRAF
13 positive regulation of protein kinase B signaling GO:0051897 9.99 PIK3CA FGFR3 ERBB2 EGFR
14 positive regulation of protein phosphorylation GO:0001934 9.98 RAF1 KRAS HRAS ERBB2 EGFR
15 positive regulation of MAPK cascade GO:0043410 9.97 HRAS FGFR3 ERBB2 CTNNB1
16 protein autophosphorylation GO:0046777 9.97 STK11 FGFR3 ERBB2 EGFR ALK
17 positive regulation of gene expression GO:0010628 9.97 TP53 PRKN NFE2L2 MAP2K1 KRAS HRAS
18 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.95 RAF1 NRAS KRAS HRAS
19 negative regulation of neuron apoptotic process GO:0043524 9.93 PRKN PIK3CA KRAS HRAS BRAF
20 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 RAF1 PIK3CA EGFR BRAF
21 liver development GO:0001889 9.91 PIK3CA KRAS HRAS EGFR
22 regulation of cell proliferation GO:0042127 9.91 TP53 SMAD4 EGFR CTNNB1 CDK4 BRAF
23 phosphorylation GO:0016310 9.9 STK11 ROS1 RAF1 PIK3CA MAP2K1 FGFR3
24 negative regulation of cell death GO:0060548 9.89 SMAD4 PRKN NFE2L2
25 cellular response to growth factor stimulus GO:0071363 9.89 ERBB2 EGFR CTNNB1
26 positive regulation of epithelial cell proliferation GO:0050679 9.89 HRAS ERBB2 EGFR
27 Ras protein signal transduction GO:0007265 9.89 TP53 NRAS KRAS HRAS
28 cell cycle arrest GO:0007050 9.89 TP53 STK11 MAP2K1 HRAS APC
29 somatic stem cell population maintenance GO:0035019 9.88 SMAD4 RAF1 BRAF
30 cellular response to drug GO:0035690 9.88 TP53 NFE2L2 EGFR BRAF
31 epidermal growth factor receptor signaling pathway GO:0007173 9.86 PIK3CA EGFR BRAF
32 activation of MAPKK activity GO:0000186 9.86 RAF1 EGFR BRAF
33 positive regulation of MAP kinase activity GO:0043406 9.86 KRAS HRAS ERBB2 EGFR
34 regulation of cell differentiation GO:0045595 9.85 RAF1 CTNNB1 APC
35 positive regulation of axonogenesis GO:0050772 9.85 STK11 MAP2K1 BRAF
36 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 ROS1 FGFR3 ERBB2 EGFR ALK
37 regulation of cell motility GO:2000145 9.84 RAF1 ERBB2 EGFR
38 ERBB2 signaling pathway GO:0038128 9.83 PIK3CA ERBB2 EGFR
39 regulation of ERK1 and ERK2 cascade GO:0070372 9.83 ROS1 ERBB2 EGFR
40 vasculature development GO:0001944 9.83 STK11 PIK3CA CTNNB1
41 positive regulation of kinase activity GO:0033674 9.83 ROS1 FGFR3 ERBB2 EGFR ALK
42 thyroid gland development GO:0030878 9.8 RAF1 MAP2K1 BRAF
43 peptidyl-tyrosine phosphorylation GO:0018108 9.8 ROS1 MAP2K1 FGFR3 ERBB2 EGFR BRAF
44 thymus development GO:0048538 9.78 RAF1 MAP2K1 CTNNB1 BRAF
45 face development GO:0060324 9.77 RAF1 MAP2K1 BRAF
46 anoikis GO:0043276 9.72 STK11 PIK3CA
47 regulation of microtubule-based process GO:0032886 9.72 ERBB2 APC
48 regulation of axon regeneration GO:0048679 9.71 MAP2K1 BRAF
49 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.7 TP53 NFE2L2
50 response to isolation stress GO:0035900 9.7 KRAS HRAS

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.48 TP53 STK11 SMAD4 ROS1 RAF1 PRKN
2 transferase activity GO:0016740 10.21 STK11 ROS1 RAF1 PRKN PIK3CA MAP2K1
3 identical protein binding GO:0042802 10.15 TP53 SMAD4 RAF1 PRKN FGFR3 ERBB2
4 ATP binding GO:0005524 10.1 TP53 STK11 ROS1 RAF1 PIK3CA MAP2K1
5 protein serine/threonine kinase activity GO:0004674 9.99 STK11 RAF1 PIK3CA MAP2K1 CDK4 BRAF
6 protein kinase binding GO:0019901 9.98 TP53 PRKN EGFR CTNNB1 APC
7 protein-containing complex binding GO:0044877 9.97 RAF1 PRKN NRAS KRAS HRAS EGFR
8 enzyme binding GO:0019899 9.93 TP53 RAF1 PRKN EGFR CTNNB1
9 protein C-terminus binding GO:0008022 9.87 MAP2K1 HRAS ERBB2 CTNNB1
10 protein phosphatase binding GO:0019903 9.85 TP53 ROS1 ERBB2 EGFR CTNNB1
11 protein kinase activity GO:0004672 9.85 STK11 ROS1 RAF1 MAP2K1 FGFR3 ERBB2
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.8 ROS1 FGFR3 ERBB2 EGFR ALK
13 protein tyrosine kinase activity GO:0004713 9.8 ROS1 MAP2K1 FGFR3 ERBB2 EGFR BRAF
14 nucleotide binding GO:0000166 9.8 STK11 ROS1 RAF1 PIK3CA NRAS MAP2K1
15 GDP binding GO:0019003 9.75 NRAS KRAS HRAS
16 RNA polymerase II transcription factor binding GO:0001085 9.73 TP53 SMAD4 CTNNB1
17 MAP kinase kinase kinase activity GO:0004709 9.7 RAF1 EGFR BRAF
18 I-SMAD binding GO:0070411 9.59 SMAD4 CTNNB1
19 LRR domain binding GO:0030275 9.55 STK11 KRAS
20 kinase activity GO:0016301 9.36 STK11 ROS1 RAF1 PIK3CA MAP2K1 FGFR3

Sources for Lung Cancer Susceptibility 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....